Peritoneal neuroendocrine carcinoma of unknown primary with markedly elevated alpha-fetoprotein: a case report
4 affiliations
- 1Department of Infectious Diseases, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital , , ,
- 2Department of Gastrointestinal Surgery, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital , , ,
- 3Department of Pathology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital , , ,
- 4Department of Medical Affairs, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital , , ,
Abstract
Background: Peritoneal neuroendocrine carcinoma(NEC) is primarily metastatic, with primary cases being exceedingly rare. The relationship between alpha-fetoprotein(AFP) and neuroendocrine carcinoma remains unclear. In this report, we present a patient with peritoneal neuroendocrine carcinoma who exhibited significantly elevated AFP levels. Extensive evaluation revealed no obvious primary site outside the peritoneum; however, occult gastrointestinal origin could not be entirely excluded. The tumor was thus classified as NEC of unknown primary, with a presumed primary peritoneal origin. The findings from this case suggest that markedly elevated AFP may be associated with aggressive tumor behavior and could serve as a potential marker for monitoring disease activity in peritoneal NECs, a hypothesis that warrants further investigation.
Case presentation: A 51-year-old man with massive ascites and elevated AFP levels was admitted to the hospital. Liver enhanced magnetic resonance imaging and gastrointestinal endoscopy did not reveal any space-occupying lesions, while abdominal puncture did not detect tumor cells. The patient’s whole-body PET-CT revealed extensive peritoneal thickening and increased FDG metabolism. Subsequent laparoscopic exploration revealed numerous nodules and masses of varying sizes with a firm texture in the greater omentum, small intestine surface, mesentery, and parietal peritoneum. Immunohistochemistry of the omentum demonstrated positive results for AE1/AE3, Syn, CgA, and AFP, leading to a final diagnosis of large cell NEC of unknown primary, with a presumed primary peritoneal origin. Due to the presence of multiple peritoneal nodules, radical surgery was not feasible, and EP combined with camrelizumab was initiated. AFP levels showed an overall progressive increase, peaking at 5315 ng/mL on May 25, with a slight subsequent decline to 4948.4 ng/mL on June 20. Unfortunately, the patient discontinued chemotherapy after two cycles due to severe nausea and vomiting; he subsequently succumbed to the disease.
Conclusions: We propose the hypothesis that dynamic changes in AFP levels could reflect tumor burden and treatment response in a subset of AFP-producing NECs. However, this hypothesis requires validation in larger cohort studies. It is also important to distinguish its potential role as a monitoring biomarker from an established prognostic biomarker.
Related
- Sertoli-Leydig Cell Tumour With Heterologous Elements Presenting as Hyperandrogenaemia and Markedly Elevated Alpha-Fetoprotein: A Challenging Diagnosis.
- Case Report: Prostatic infarction mimicking prostate cancer in a patient with markedly elevated prostate-specific antigen
- Low‐Titre ANA Late‐Onset Systemic Lupus Erythematosus Presenting With Pleural Effusion and Markedly Elevated Pleural Adenosine Deaminase Mimicking Tuberculous Pleuritis
- Markedly Elevated Serum IgE in a Patient With Thrombocytopenia and a TUBA8 Variant of Uncertain Significance: A Case Report
- Revisiting alpha-fetoprotein thresholds for hepatocellular carcinoma surveillance in the metabolic dysfunction-associated steatotic liver disease era: time for an evidence-based recalibration.
BibTeX
@article{yang2026peritoneal,
title = {{Peritoneal neuroendocrine carcinoma of unknown primary with markedly elevated alpha-fetoprotein: a case report}},
author = {Jie Yang and Yaxin Zhang and Haifeng Que and Weibo Mao and Bitong He and Yinxia Wu},
journal = {Frontiers in endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1962119},
url = {https://europepmc.org/article/PMC/PMC13672027},
note = {CC BY},
}
RIS
TY - JOUR
TI - Peritoneal neuroendocrine carcinoma of unknown primary with markedly elevated alpha-fetoprotein: a case report
AU - Jie Yang
AU - Yaxin Zhang
AU - Haifeng Que
AU - Weibo Mao
AU - Bitong He
AU - Yinxia Wu
PY - 2026
DA - 2026/10/02
JO - Frontiers in endocrinology
DO - 10.3389/fendo.2026.1962119
UR - https://europepmc.org/article/PMC/PMC13672027
AB - Background: Peritoneal neuroendocrine carcinoma(NEC) is primarily metastatic, with primary cases being exceedingly rare. The relationship between alpha-fetoprotein(AFP) and neuroendocrine carcinoma remains unclear. In this report, we present a patient with peritoneal neuroendocrine carcinoma who exhibited significantly elevated AFP levels. Extensive evaluation revealed no obvious primary site outside the peritoneum; however, occult gastrointestinal origin could not be entirely excluded. The tumor was thus classified as NEC of unknown primary, with a presumed primary peritoneal origin. The findings from this case suggest that markedly elevated AFP may be associated with aggressive tumor behavior and could serve as a potential marker for monitoring disease activity in peritoneal NECs, a hypothesis that warrants further investigation. Case presentation: A 51-year-old man with massive ascites and elevated AFP levels was admitted to the hospital. Liver enhanced magnetic resonance imaging and gastrointestinal endoscopy did not reveal any space-occupying lesions, while abdominal puncture did not detect tumor cells. The patient’s whole-body PET-CT revealed extensive peritoneal thickening and increased FDG metabolism. Subsequent laparoscopic exploration revealed numerous nodules and masses of varying sizes with a firm texture in the greater omentum, small intestine surface, mesentery, and parietal peritoneum. Immunohistochemistry of the omentum demonstrated positive results for AE1/AE3, Syn, CgA, and AFP, leading to a final diagnosis of large cell NEC of unknown primary, with a presumed primary peritoneal origin. Due to the presence of multiple peritoneal nodules, radical surgery was not feasible, and EP combined with camrelizumab was initiated. AFP levels showed an overall progressive increase, peaking at 5315 ng/mL on May 25, with a slight subsequent decline to 4948.4 ng/mL on June 20. Unfortunately, the patient discontinued chemotherapy after two cycles due to severe nausea and vomiting; he subsequently succumbed to the disease. Conclusions: We propose the hypothesis that dynamic changes in AFP levels could reflect tumor burden and treatment response in a subset of AFP-producing NECs. However, this hypothesis requires validation in larger cohort studies. It is also important to distinguish its potential role as a monitoring biomarker from an established prognostic biomarker.
SN - 1664-2392
ER -